Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 93 clinical trials
Featured trial
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or

daratumumab
refractory multiple myeloma
  • 186 views
  • 10 May, 2022
  • 28 locations
Daratumumab and Belatacept for Desensitization (ATTAIN)

study is to find out whether two drugs, daratumumab (Darzalex®), and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney

  • 0 views
  • 24 Mar, 2022
  • 1 location
Treatment of POEMS Syndrome With Daratumumab

This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy

  • 4 views
  • 04 Oct, 2022
  • 1 location
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor

neutrophil count
lenalidomide
platelet count
growth factor
dexamethasone
  • 22 views
  • 05 Mar, 2022
  • 15 locations
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with

  • 0 views
  • 09 Jul, 2022
  • 1 location
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant

neutrophil count
daratumumab
ejection fraction
growth factor
platelet count
  • 2 views
  • 03 Feb, 2022
  • 1 location
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

achieved after first-line therapy. Currently, daratumumab (Dara) is approved by the american FDA and EMA in combination with lenalidomide (Len) and dexamethasone (Dex) or bortezomib and Dex for the

lenalidomide
azoospermia
line of therapy
remission
dexamethasone
  • 0 views
  • 02 Jul, 2022
  • 1 location
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor

carbon monoxide
diffusion capacity of the lung for carbon monoxide
ejection fraction
cyclophosphamide
tumor cells
  • 0 views
  • 29 Mar, 2021
  • 1 location
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 16 Feb, 2022
  • 1 location
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

" PETHEMA arm for fit elderly VMP x 9 + Rd x 9 (arm 1, control arm), a KRd regimen (arm 2a) (18 cycles) or a Carfilzomib-lenalidomida-dexametasona regimen combined with DARATUMUMAB (arm 2b) (18 cycles

  • 13 views
  • 24 Mar, 2021
  • 89 locations